Shawn Cross Sells 15,896 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) CFO Shawn Cross sold 15,896 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $25.03, for a total value of $397,876.88. Following the transaction, the chief financial officer owned 56,250 shares of the company’s stock, valued at $1,407,937.50. This trade represents a 22.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shawn Cross also recently made the following trade(s):

• On Wednesday, December 10th, Shawn Cross sold 9,104 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.14, for a total value of $228,874.56.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock traded up $0.55 during mid-day trading on Thursday, hitting $25.73. 1,121,447 shares of the stock were exchanged, compared to its average volume of 639,245. Pacira BioSciences, Inc. has a 12 month low of $18.17 and a 12 month high of $27.64. The company has a 50-day simple moving average of $23.11 and a 200 day simple moving average of $24.15. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.78 and a current ratio of 5.26. The company has a market capitalization of $1.11 billion, a P/E ratio of 57.18 and a beta of 0.23.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, November 6th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. The business had revenue of $179.52 million during the quarter, compared to the consensus estimate of $182.86 million. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.The firm’s revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.79 EPS. Sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on PCRX. Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Barclays began coverage on shares of Pacira BioSciences in a research report on Tuesday. They set an “equal weight” rating and a $27.00 target price for the company. Truist Financial reduced their target price on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a research note on Monday. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Hantz Financial Services Inc. increased its holdings in Pacira BioSciences by 175.4% in the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after buying an additional 721 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Pacira BioSciences during the 1st quarter worth about $51,000. Tidemark LLC purchased a new stake in Pacira BioSciences during the third quarter valued at about $56,000. Brooklyn Investment Group increased its position in shares of Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock worth $56,000 after acquiring an additional 1,764 shares in the last quarter. Finally, US Bancorp DE lifted its position in Pacira BioSciences by 31.0% during the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock worth $56,000 after acquiring an additional 537 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.